Detail akcie NovoCure NPV online

Business Summary: NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Novocure Ltd revenues increased 12% to $155M. Net loss decreased 11% to $34.3M. Revenues reflect Germany segment increase of 19% to $18.7M, United States segment increase of 3% to $93.2M, Japan segment increase of 11% to $8.7M. Lower net loss reflects Proprietary platform technology segment loss decrease of 9% to $37.9M.